Avalo Therapeutics 从 AlmataBio 收购了已进入 2 期阶段的抗 IL-1β 单克隆抗体 AVTX-009，并筹集了 1.85 亿美元融资。 Avalo Therapeutics acquires Phase 2-ready anti-IL-1β mAb AVTX-009 from AlmataBio and raises $185M in financing.

Avalo Therapeutics 从私人控股公司 AlmataBio 收购了已进入第二阶段的抗 IL-1β 单克隆抗体 AVTX-009，并宣布进行高达 1.85 亿美元的私募融资。 Avalo Therapeutics acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, from privately held AlmataBio, and announces a private placement financing of up to $185 million. 此次私募融资包括 1.156 亿美元的初始前期投资，并将 Avalo 的现金跑道延长至 2027 年。 The private placement financing includes an initial upfront investment of $115.6 million and extends Avalo's cash runway into 2027. 计划中的化脓性汗腺炎 2 期试验预计将于 2026 年获得主要结果。 Topline results from the planned Phase 2 trial in hidradenitis suppurativa are expected in 2026.